Citigroup Inc. reduced its stake in ImmunityBio, Inc. (NASDAQ:IBRX – Get Rating) by 43.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 212,605 shares of the company’s stock after selling 161,039 shares during the period. Citigroup Inc. owned 0.05% of ImmunityBio worth $1,078,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Metropolitan Life Insurance Co NY increased its stake in ImmunityBio by 168.6% in the third quarter. Metropolitan Life Insurance Co NY now owns 4,953 shares of the company’s stock valued at $25,000 after purchasing an additional 3,109 shares in the last quarter. Nisa Investment Advisors LLC bought a new stake in shares of ImmunityBio during the third quarter worth about $27,000. Point72 Hong Kong Ltd increased its position in shares of ImmunityBio by 2,136.0% during the first quarter. Point72 Hong Kong Ltd now owns 6,149 shares of the company’s stock worth $34,000 after acquiring an additional 5,874 shares in the last quarter. Toroso Investments LLC bought a new stake in shares of ImmunityBio during the first quarter worth about $63,000. Finally, Cambridge Investment Research Advisors Inc. bought a new stake in shares of ImmunityBio during the fourth quarter worth about $61,000. 9.86% of the stock is owned by institutional investors.
Analysts Set New Price Targets
Separately, Piper Sandler downgraded shares of ImmunityBio from an “overweight” rating to a “neutral” rating and decreased their target price for the stock from $10.00 to $4.00 in a research report on Friday, May 12th.
ImmunityBio Stock Performance
Shares of IBRX stock opened at $2.54 on Tuesday. The firm’s 50 day moving average is $2.60 and its 200 day moving average is $3.71. ImmunityBio, Inc. has a 12 month low of $1.21 and a 12 month high of $7.80.
ImmunityBio Profile
ImmunityBio, Inc is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company’s immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory.
Further Reading
Want to see what other hedge funds are holding IBRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ImmunityBio, Inc. (NASDAQ:IBRX – Get Rating).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider ImmunityBio, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and ImmunityBio wasn’t on the list.
While ImmunityBio currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Source: marketbeat.com
